Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EROX Corp and pheremones -- Ignore unavailable to you. Want to Upgrade?

To: Terror who wrote (493)	7/15/1998 10:15:00 AM
From: daaan	Read Replies (1) \| Respond to of 562

I was "introduced" to EROX via a CNBC anal-ist. Bought 2000 at $8. What a pump and dump. How did you find this POS?

To: Terror who wrote (493)	7/15/1998 10:48:00 AM
From: bill northington	Respond to of 562

Marcie, looks to me like another dead cat bounce. remember it is better to be pissed off then pissed on. who or whatever was buying sure does not know what he /she is doing Bill

To: Terror who wrote (493)	8/6/1998 10:08:00 AM
From: trofala	Read Replies (1) \| Respond to of 562

FREMONT, Calif., Aug. 5 /PRNewswire/ -- Human Pheromone Sciences, Inc. (Nasdaq: EROX - news), the first and only company to be granted patents for inclusion of synthesized human pheromones in consumer products today announced a net loss of $1,395,871 ($0.14 per share) on net sales of 1,905,257 for its second quarter ended June 30, 1998, compared with a net loss for the prior year quarter of $3,937,917, or ($0.38 per share) on net sales of $3,817,542. For the six months, the net loss was reduced to $2,168,941 ($0.21 per share) from $3,748,434 ($0.37 per share) in 1997 on sales of $5,268,418 as compared with $8,913,831 in the prior year six months. Included in the current year quarter is a provision for expenses to be incurred in connection with a planned operating management reorganization. In analyzing the results for the quarter and the six months periods, William P. Horgan, Chief Executive Officer, noted that sales of the Company's core products, REALM(R) Men and Realm(R) Women, the first and only products to contain synthesized human pheromones, were slightly behind prior year sales levels, reflecting a malaise in the prestige-priced fragrances in U.S. department stores. ''The vast majority of the sales shortfall from the prior year is a result of approximately $3.6 million in shipments in connection with the introduction of the inner Realm(R) fragrance line into the better department stores in 1997. The continued weakness of the brand in this class of trade resulted in minimal sales in 1998, and the Company recorded approximately $650,000 in retailer returns during the most recent six months,'' Horgan stated. In response to this ongoing pattern, the Company has recently undertaken several programs designed to segment its selling and marketing approach for each of the product lines. REALM product will continue to be promoted in the better department stores and selected international and secondary markets. inner REALM will be the lynchpin of a series of human pheromone products offered in the more price-sensitive secondary markets and sold through the Company's distributor network. This strategy is intended to eliminate product confusion in the department stores and to make the Company's patented technology available to a broader range of consumers as it enters the important holiday season